Precipio (NASDAQ:PRPO) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Precipio, Inc. (NASDAQ:PRPO) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $25.17 and traded as low as $22.95. Precipio shares last traded at $25.24, with a volume of 170,506 shares traded.

Analyst Upgrades and Downgrades

PRPO has been the topic of several analyst reports. Wall Street Zen downgraded Precipio from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Precipio Stock Up 8.8%

The stock has a market capitalization of $45.18 million, a P/E ratio of -53.70 and a beta of 1.27. The company has a current ratio of 1.56, a quick ratio of 1.33 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average is $24.42 and its 200-day moving average is $25.17.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. The firm had revenue of $6.71 million for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.

Institutional Investors Weigh In On Precipio

A number of hedge funds and other institutional investors have recently bought and sold shares of PRPO. Renaissance Technologies LLC boosted its stake in Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 1,400 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of Precipio in the third quarter valued at about $194,000. 10.45% of the stock is owned by institutional investors and hedge funds.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.